Cargando…
Carbonic Anhydrase I as a New Plasma Biomarker for Prostate Cancer
Serum prostate-specific antigen (PSA) levels ranging from 4 to 10 ng/mL is considered a diagnostic gray zone for detecting prostate cancer because biopsies reveal no evidence of cancer in 75% of these subjects. Our goal was to discover a new highly specific biomarker for prostate cancer by analyzing...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scholarly Research Network
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506895/ https://www.ncbi.nlm.nih.gov/pubmed/23213568 http://dx.doi.org/10.5402/2012/768190 |
_version_ | 1782250974577950720 |
---|---|
author | Takakura, Michiko Yokomizo, Akira Tanaka, Yoshinori Kobayashi, Michimoto Jung, Giman Banno, Miho Sakuma, Tomohiro Imada, Kenjiro Oda, Yoshinao Kamita, Masahiro Honda, Kazufumi Yamada, Tesshi Naito, Seiji Ono, Masaya |
author_facet | Takakura, Michiko Yokomizo, Akira Tanaka, Yoshinori Kobayashi, Michimoto Jung, Giman Banno, Miho Sakuma, Tomohiro Imada, Kenjiro Oda, Yoshinao Kamita, Masahiro Honda, Kazufumi Yamada, Tesshi Naito, Seiji Ono, Masaya |
author_sort | Takakura, Michiko |
collection | PubMed |
description | Serum prostate-specific antigen (PSA) levels ranging from 4 to 10 ng/mL is considered a diagnostic gray zone for detecting prostate cancer because biopsies reveal no evidence of cancer in 75% of these subjects. Our goal was to discover a new highly specific biomarker for prostate cancer by analyzing plasma proteins using a proteomic technique. Enriched plasma proteins from 25 prostate cancer patients and 15 healthy controls were analyzed using a label-free quantitative shotgun proteomics platform called 2DICAL (2-dimensional image converted analysis of liquid chromatography and mass spectrometry) and candidate biomarkers were searched. Among the 40,678 identified mass spectrum (MS) peaks, 117 peaks significantly differed between prostate cancer patients and healthy controls. Ten peaks matched carbonic anhydrase I (CAI) by tandem MS. Independent immunological assays revealed that plasma CAI levels in 54 prostate cancer patients were significantly higher than those in 60 healthy controls (P = 0.022, Mann-Whitney U test). In the PSA gray-zone group, the discrimination rate of prostate cancer patients increased by considering plasma CAI levels. CAI can potentially serve as a valuable plasma biomarker and the combination of PSA and CAI may have great advantages for diagnosing prostate cancer in patients with gray-zone PSA level. |
format | Online Article Text |
id | pubmed-3506895 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | International Scholarly Research Network |
record_format | MEDLINE/PubMed |
spelling | pubmed-35068952012-12-04 Carbonic Anhydrase I as a New Plasma Biomarker for Prostate Cancer Takakura, Michiko Yokomizo, Akira Tanaka, Yoshinori Kobayashi, Michimoto Jung, Giman Banno, Miho Sakuma, Tomohiro Imada, Kenjiro Oda, Yoshinao Kamita, Masahiro Honda, Kazufumi Yamada, Tesshi Naito, Seiji Ono, Masaya ISRN Oncol Clinical Study Serum prostate-specific antigen (PSA) levels ranging from 4 to 10 ng/mL is considered a diagnostic gray zone for detecting prostate cancer because biopsies reveal no evidence of cancer in 75% of these subjects. Our goal was to discover a new highly specific biomarker for prostate cancer by analyzing plasma proteins using a proteomic technique. Enriched plasma proteins from 25 prostate cancer patients and 15 healthy controls were analyzed using a label-free quantitative shotgun proteomics platform called 2DICAL (2-dimensional image converted analysis of liquid chromatography and mass spectrometry) and candidate biomarkers were searched. Among the 40,678 identified mass spectrum (MS) peaks, 117 peaks significantly differed between prostate cancer patients and healthy controls. Ten peaks matched carbonic anhydrase I (CAI) by tandem MS. Independent immunological assays revealed that plasma CAI levels in 54 prostate cancer patients were significantly higher than those in 60 healthy controls (P = 0.022, Mann-Whitney U test). In the PSA gray-zone group, the discrimination rate of prostate cancer patients increased by considering plasma CAI levels. CAI can potentially serve as a valuable plasma biomarker and the combination of PSA and CAI may have great advantages for diagnosing prostate cancer in patients with gray-zone PSA level. International Scholarly Research Network 2012-11-19 /pmc/articles/PMC3506895/ /pubmed/23213568 http://dx.doi.org/10.5402/2012/768190 Text en Copyright © 2012 Michiko Takakura et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Takakura, Michiko Yokomizo, Akira Tanaka, Yoshinori Kobayashi, Michimoto Jung, Giman Banno, Miho Sakuma, Tomohiro Imada, Kenjiro Oda, Yoshinao Kamita, Masahiro Honda, Kazufumi Yamada, Tesshi Naito, Seiji Ono, Masaya Carbonic Anhydrase I as a New Plasma Biomarker for Prostate Cancer |
title | Carbonic Anhydrase I as a New Plasma Biomarker for Prostate Cancer |
title_full | Carbonic Anhydrase I as a New Plasma Biomarker for Prostate Cancer |
title_fullStr | Carbonic Anhydrase I as a New Plasma Biomarker for Prostate Cancer |
title_full_unstemmed | Carbonic Anhydrase I as a New Plasma Biomarker for Prostate Cancer |
title_short | Carbonic Anhydrase I as a New Plasma Biomarker for Prostate Cancer |
title_sort | carbonic anhydrase i as a new plasma biomarker for prostate cancer |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506895/ https://www.ncbi.nlm.nih.gov/pubmed/23213568 http://dx.doi.org/10.5402/2012/768190 |
work_keys_str_mv | AT takakuramichiko carbonicanhydraseiasanewplasmabiomarkerforprostatecancer AT yokomizoakira carbonicanhydraseiasanewplasmabiomarkerforprostatecancer AT tanakayoshinori carbonicanhydraseiasanewplasmabiomarkerforprostatecancer AT kobayashimichimoto carbonicanhydraseiasanewplasmabiomarkerforprostatecancer AT junggiman carbonicanhydraseiasanewplasmabiomarkerforprostatecancer AT bannomiho carbonicanhydraseiasanewplasmabiomarkerforprostatecancer AT sakumatomohiro carbonicanhydraseiasanewplasmabiomarkerforprostatecancer AT imadakenjiro carbonicanhydraseiasanewplasmabiomarkerforprostatecancer AT odayoshinao carbonicanhydraseiasanewplasmabiomarkerforprostatecancer AT kamitamasahiro carbonicanhydraseiasanewplasmabiomarkerforprostatecancer AT hondakazufumi carbonicanhydraseiasanewplasmabiomarkerforprostatecancer AT yamadatesshi carbonicanhydraseiasanewplasmabiomarkerforprostatecancer AT naitoseiji carbonicanhydraseiasanewplasmabiomarkerforprostatecancer AT onomasaya carbonicanhydraseiasanewplasmabiomarkerforprostatecancer |